Stephen K. L. Chia, Andrew David Redfern, Jean-Pierre M. Ayoub, Haji I. Chalchal, Daniel Rayson, Moira Rushton, Christine Desbiens, Dhanusha Sabanathan, Jacques Raphael, Angela Chan, Jessica Singh, Christine E. Simmons, Nicholas Zdenkowski, Sheridan Wilson, Danielle Rodin, David W. Cescon, Frauke Schimmoller, Lisa Gallinaro, Bingshu E. Chen, Wendy R. Parulekar. "A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.17_suppl.lba1005